Last week Boston Scientific (Natick, Massachusetts) added Atritech (Plymouth, Minnesota) to its shopping list, announcing its intention to acquire the company for $100 million upfront plus potential payments of up to $275 million. The deal gives Boston Scientific a device backed by strong clinical evidence and puts the company in an ideal position in the endocardio left atrial appendage (LAA) market, according to Karene Dumoulin, principal analyst of cardiovascular at Millennium Research Group (MRG; New York). (Medical Device Daily) Read More
